Understanding and targeting resistance mechanisms in NSCLC

Nature Reviews Cancer 17, 637 (2017). doi:10.1038/nrc.2017.84 Authors: Julia Rotow & Trever G. Bivona The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances,
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research